▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cheryl Swanson

CherylSwanson

Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson

Recent Articles by Cheryl Swanson

503893639

Oct 20, 2016 by Cheryl Swanson

Move Over, Intuitive Surgical, Here's How Johnson & Johnson and Google Plan to Build a Better Robot

With J&J and Google planning to build a robotic assistant the size of Star Wars' C-3PO -- and almost as smart as WALL-E -- Intuitive Surgical may need to step up its game.

96162150

Sep 14, 2016 by Cheryl Swanson

You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne

This Big Pharma is advancing a revolutionary dual HIV therapy that could give Gilead a run for its money and change the standard of care for HIV.

186201544

Sep 13, 2016 by Cheryl Swanson

Why Allergan Should Start Paying a Dividend

A dividend would make this stock appealing to long-term investors, and with its newfound cash bounty, Allergan can certainly afford it.

114934842

Sep 13, 2016 by Cheryl Swanson

Why Pfizer's Stock Is a Big Gamble Right Now

While Pfizer’s recent M&A deals are focused on rebuilding, three near-term risks could bring the walls crumbling down.

124871552

Sep 12, 2016 by Cheryl Swanson

How the Tides Are Turning in Alzheimer's Research

By aiming their drug candidates at earlier stages of the disease, Biogen and Lilly may be closing in on an effective treatment.

printing money hundred dollar bills cash

Sep 12, 2016 by Cheryl Swanson

The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working

In an industry under fire for sky-high drug pricing, GlaxoSmithKline is blazing a new trail.

184935915

Sep 11, 2016 by Cheryl Swanson

3 Great Dividend Stocks in the Bargain Bin for Retirees

Short-term disappointments have tossed these three stand-out stocks on the discount rack.

Google

Sep 3, 2016 by Cheryl Swanson

How Google Plans to Reinvent Healthcare

The tech titan wants to change the future of healthcare. But first, it needs to come up with a useful product.

533790590

Sep 1, 2016 by Cheryl Swanson

Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags Remain

A recently granted priority review has this stock jumping, but watch out. The company's chequered history merits caution.

0000seniorsdancing

Aug 31, 2016 by Cheryl Swanson

3 Dividend Stocks to Make Your Retirement Sweeter

These companies should keep raising their dividends while you find fun things to do when you retire.

170886670

Aug 29, 2016 by Cheryl Swanson

Thermo Fisher to Buy Illumina? Not So Fast

The rumors of a $30 billion megamerger likely don’t hold water, but they could still point to some upside in gene-sequencing stocks.

MF2Pfizerbestdays

Aug 27, 2016 by Cheryl Swanson

Could Toxicity Issues Topple CAR-T Cancer Therapies?

After deadly clinical trials, should investors fear safety issues might further delay or even topple CAR-T therapies and stocks?

MFpfizer2

Aug 26, 2016 by Cheryl Swanson

Game On for Pfizer With $14 Billion Medivation Buyout (or, Why Pfizer's Buyout of Medivation Could Be a Smart Move)

Pfizer's knockout $14 billion acquisition of Medivation shocked even the most optimistic biotech bulls. But here’s why the giant pharma jumped into this deal with both feet.

MFALLERGAN152890964

Aug 22, 2016 by Cheryl Swanson

Allergan Makes an Eye-Opening Acquisition

Allergan is back on the hunt for deals -- but not the ones you might expect.

MF1

Aug 21, 2016 by Cheryl Swanson

3 Reasons Medivation Is the Juiciest Target in Biotech

Seemingly half the world's pharma companies are chasing this relatively unknown biotech. Here's why.

88338768

Aug 18, 2016 by Cheryl Swanson

Why I Hate Johnson & Johnson Right Now (But I'll Never Sell)

With a key patent for Remicade just invalidated and a copycat drug looming, J&J may be due for a haircut.

00000pfizercogana

Aug 18, 2016 by Cheryl Swanson

Why Pfizer's Acquisition of Anacor Is a Great Fit

This boron-based biotech could open some exciting drug-development pathways for Pfizer.

00000pfizer

Aug 16, 2016 by Cheryl Swanson

Pfizer's Bold Bid to Conquer Cancer

Pfizer is hustling to become an oncology powerhouse, which could pay off big time for investors and patients.

0000hugetwist

Jul 27, 2016 by Cheryl Swanson

The Drug-Price War Just Took a Big New Twist

As states and insurers are forced to unlock access to pricey hep-C wonder drugs, the wind may be shifting in favor of biotech and pharma investors.

0000soaring

Jul 19, 2016 by Cheryl Swanson, Cory Renauer, and Brian Feroldi

3 Biotech Stocks That Could Soar Over the Next 12 Months

Biotech is down, but not out. In fact, our contributors see these three stocks as great bets for an explosive recovery.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services